In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Europe's Flavors of Sustainable BioPharma

Executive Summary

Europe's financing environment makes it difficult to build big biotech from scratch. But sustainable biopharma firms are nevertheless emerging--mostly through the transformation of existing pharma assets.

Related Content

Organon Reboots with Biotech
German Biotech: Coalescing around the Haves
Bayer: Out of Trouble Come Opportunities
In Endo, Vernalis Finds a Believer in Frova
European Financing: The Money's Back, But How Do You Get It?
Bioteching UCB-and Maybe Mid-Sized Pharma, Too
Jumpstart to Products
The Best Defense Is a Good Offense: Sanofi's Bid for Aventis
BioVitrum/Amgen: A Sign of Early-Stage Deals to Come
Biotech's Euro-Marketing Gambit


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts